Friday, February 23, 2018 5:42:51 PM
Email Correspondence dated February 19, 2018
From: Lyron Bentovim
Sent: Monday, February 19, 2018
To: Shlomi Palas
Shlomi,
I reviewed the document (last evening’s version) and spent a sleepless night thinking about it, I don’t see how this agreement serves the interests on current shareholders or even of the company at large. Therefore I don’t see myself supporting this proposal.
It is clear this is the direction you want to proceed, please call me so we can agree on the best way to proceed. I am available until 8:30 AM.
Lyron
Lyron L. Bentovim
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM